Aeterna Zentaris Inc. - Product Pipeline Review - 2016

1 of 4
Aeterna Zentaris Inc. - Product Pipeline Review - 2016

Summary

‘Aeterna Zentaris Inc. - Product Pipeline Review - 2016’, provides an overview of the Aeterna Zentaris Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Aeterna Zentaris Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Aeterna Zentaris Inc.
- The report provides overview of Aeterna Zentaris Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Aeterna Zentaris Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Aeterna Zentaris Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Aeterna Zentaris Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Aeterna Zentaris Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aeterna Zentaris Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Aeterna Zentaris Inc. Snapshot

Aeterna Zentaris Inc. Overview

Key Information

Key Facts

Aeterna Zentaris Inc. - Research and Development Overview

Key Therapeutic Areas

Aeterna Zentaris Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Aeterna Zentaris Inc. - Pipeline Products Glance

Aeterna Zentaris Inc. - Late Stage Pipeline Products

Phase III Products/Combination Treatment Modalities

Aeterna Zentaris Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Aeterna Zentaris Inc. - Early Stage Pipeline Products

IND/CTA Filed Products/Combination Treatment Modalities

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Aeterna Zentaris Inc. - Drug Profiles

zoptarelin doxorubicin

Product Description

Mechanism of Action

R&D Progress

macimorelin acetate

Product Description

Mechanism of Action

R&D Progress

ozarelix

Product Description

Mechanism of Action

R&D Progress

AEZS-120

Product Description

Mechanism of Action

R&D Progress

AEZS-124

Product Description

Mechanism of Action

R&D Progress

AEZS-125

Product Description

Mechanism of Action

R&D Progress

AEZS-126

Product Description

Mechanism of Action

R&D Progress

AEZS-134

Product Description

Mechanism of Action

R&D Progress

AEZS-138

Product Description

Mechanism of Action

R&D Progress

AEZS-140

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Undisclosed Indication

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit ERK2 and Aurora B Kinase for Oncology

Product Description

Mechanism of Action

R&D Progress

Aeterna Zentaris Inc. - Pipeline Analysis

Aeterna Zentaris Inc. - Pipeline Products by Target

Aeterna Zentaris Inc. - Pipeline Products by Route of Administration

Aeterna Zentaris Inc. - Pipeline Products by Molecule Type

Aeterna Zentaris Inc. - Pipeline Products by Mechanism of Action

Aeterna Zentaris Inc. - Recent Pipeline Updates

Aeterna Zentaris Inc. - Dormant Projects

Aeterna Zentaris Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

AEZS-115

AEZS-123

AEZS-131

AEZS-132

AN-215

AN-238

perifosine

teverelix

Aeterna Zentaris Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 53List of Tables

Aeterna Zentaris Inc., Key Information

Aeterna Zentaris Inc., Key Facts

Aeterna Zentaris Inc. - Pipeline by Indication, 2016

Aeterna Zentaris Inc. - Pipeline by Stage of Development, 2016

Aeterna Zentaris Inc. - Monotherapy Products in Pipeline, 2016

Aeterna Zentaris Inc. - Out-Licensed Products in Pipeline, 2016

Aeterna Zentaris Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Aeterna Zentaris Inc. - Phase III, 2016

Aeterna Zentaris Inc. - Phase II, 2016

Aeterna Zentaris Inc. - IND/CTA Filed, 2016

Aeterna Zentaris Inc. - Preclinical, 2016

Aeterna Zentaris Inc. - Discovery, 2016

Aeterna Zentaris Inc. - Pipeline by Target, 2016

Aeterna Zentaris Inc. - Pipeline by Route of Administration, 2016

Aeterna Zentaris Inc. - Pipeline by Molecule Type, 2016

Aeterna Zentaris Inc. - Pipeline Products by Mechanism of Action, 2016

Aeterna Zentaris Inc. - Recent Pipeline Updates, 2016

Aeterna Zentaris Inc. - Dormant Developmental Projects,2016

Aeterna Zentaris Inc. - Discontinued Pipeline Products, 2016

Aeterna Zentaris Inc., Subsidiaries 51List of Figures

Aeterna Zentaris Inc. - Pipeline by Top 10 Indication, 2016

Aeterna Zentaris Inc. - Pipeline by Stage of Development, 2016

Aeterna Zentaris Inc. - Monotherapy Products in Pipeline, 2016

Aeterna Zentaris Inc. - Out-Licensed Products in Pipeline, 2016

Aeterna Zentaris Inc. - Pipeline by Top 10 Target, 2016

Aeterna Zentaris Inc. - Pipeline by Route of Administration, 2016

Aeterna Zentaris Inc. - Pipeline by Molecule Type, 2016

Aeterna Zentaris Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll